INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has successfully produced and isolated engineered exosomes (EEVs) that target and kill breast cancer cells in vitro.
In a proof-of-concept study, a breast cancer targeting protein (a chimeric antigen receptor, CAR) was expressed in exosomes released by immune cells. The modified exosomes were isolated and concentrated from immune cell-conditioned media using INOVIQ’s proprietary EXO-ACE™ technology (ASX: 20/3/24). EXO-ACE recovered more than 80% of exosomes from cell-conditioned media with over 95% purity. When treated with these exosomes, 75% of breast cancer cells underwent cell death within 72 hours. Based on these excellent results, INOVIQ will now progress its exosome therapeutics program, initially focusing on immune-cell derived exosome therapeutics for metastatic breast and ovarian cancers.
For more information, download the attached PDF.
Download this document
